Gene+
Gene+ (吉因加) is a Beijing-based AI-driven precision medicine company founded in 2015 that operates an AI multi-omics platform for biomarker discovery, NGS-based diagnostics, and drug R&D enablement, serving hospitals, pharmaceutical companies, and research institutions across China and 10+ international markets.
- Company typePrivate
- Founded2015
- HeadquartersChangping, China
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Gene+ does
Gene+ (吉因加), legally Beijing Geneplus Technology Co., Ltd. (北京吉因加科技有限公司), is a Beijing-based AI-driven precision medicine company founded in 2015 that provides genetic testing services and precision oncology solutions across China and international markets. The company operates an AI multi-omics technology platform consisting of three tightly coupled modules — an Omics Factory for high-throughput standardized multi-omics data production (genomics, transcriptomics, proteomics, metabolomics), a Bioinformatics Cloud & Database for intelligent data analysis and management, and Large Models & Agents powering AI applications — which together form a full-chain capability from biomarker discovery and validation through productization to commercialization.
Gene+ monetizes this platform through three integrated solution areas targeting enterprise customers: (1) Precision Diagnostics Solutions built on NGS innovation with fully automated intelligent platforms for hospitals; (2) Drug R&D Enablement Solutions offering biomarker discovery, inclusion/exclusion testing, virtual patient solutions, and companion diagnostics for pharmaceutical and biotechnology companies; and (3) Clinical Research & Translation Solutions providing AI4S collaboration platforms for medical research institutions. Specific commercial products include 吉知原®CAPmNGS for capture metagenomic pathogen detection and 吉迅安® for breast cancer precision diagnostics.
The company employs an enterprise field sales go-to-market model, distributing customized precision medicine solutions directly to hospitals, pharmaceutical companies, and research institutions across 30+ Chinese provinces/cities domestically and 10+ countries internationally. Pricing is not publicly disclosed and is structured around customized enterprise contracts per customer segment. The company has raised approximately $223M across multiple funding rounds since 2016, led by investors including BGI Group, CCB International, Alibaba Health, Baidu Ventures, GGV Capital, and more recently Chang Development and a Shaoxing government fund. Key regulatory milestones include CLIA certification in January 2025 (completing a 'three certifications' triad) and selection for China's National Science and Technology Innovation 2030 major project.
Gene+ firmographics
Firmographics- Name
- Gene+
- Legal name
- 北京吉因加科技有限公司
- Website
- https://geneplus.org.cn
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gene+ (吉因加) is a Beijing-based AI-driven precision medicine company founded in 2015 that operates an AI multi-omics platform for biomarker discovery, NGS-based diagnostics, and drug R&D enablement, serving hospitals, pharmaceutical companies, and research institutions across China and 10+ international markets.
- Ownership category
- akta.pro rank
Gene+ industry classification
Industry- Product category
- Precision Medicine
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
Keywords
Where Gene+ is headquartered
LocationHeadquarters
- HQ city
- Changping
- HQ country
- China
- HQ region
- Asia
Markets served
Gene+ business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Gene+ product offering
Product offeringCore offering
Gene+ (吉因加) is an AI-empowered precision medicine company that develops and operates an AI-driven multi-omics technology platform integrating biomarker discovery and validation, product development, and commercialization. It sells three categories of customized solutions — Drug R&D Enablement Solutions, Precision Diagnostics Solutions (NGS-based automated platforms), and Clinical Research & Translation Solutions — to hospitals, pharmaceutical and biotechnology companies, and medical research institutions across China and international markets.
Product overview
Gene+ is a precision medicine leader offering an AI-driven multi-omics technology platform. The company provides three integrated solution areas: Drug R&D Enablement Solutions (for pharmaceutical biomarkers and companion diagnostics), Precision Diagnostics Solutions (NGS-based clinical diagnostics), and Clinical Research & Translation Solutions (AI-powered biomarker discovery). The core AI Multi-Omics Platform consists of three tightly coupled modules (Omics Factory, Bioinformatics Cloud & Database, and Large Models & Agents) that enable the complete value chain from biomarker discovery and validation through productization to commercialization. Specific products include 吉知原®CAPmNGS (capture metagenomics pathogen detection) and 吉迅安® (breast cancer diagnostics).
Differentiator
Problem solved
Functional benefit
Brands
- 吉知原®CAPmNGS: Capture metagenome pathogen detection product.
- 吉迅安®
Products and services
- Drug R&D Enablement Solutions (药物研发赋能解决方案) Comprehensive new drug clinical trial solutions built around companion diagnostics, including biomarker discovery and validation, inclusion/exclusion testing, and virtual patient solutions, targeted at pharmaceutical and biotechnology companies.
- Precision Diagnostics Solutions (精准诊断解决方案) NGS-based precision diagnostics solutions featuring fully automated intelligent platforms integrated with multi-category diagnostic applications for hospitals and clinical laboratories.
- Clinical Research & Translation Solutions (临床科研与转化解决方案) AI multi-omics powered solutions that build AI4S collaboration platforms for disease biomarker and target discovery and validation, serving medical research institutions and translational research programs.
- 吉知原®CAPmNGS (Capture Metagenomic Pathogen Detection) Capture metagenomic pathogen detection diagnostic product (吉知原®CAPmNGS) positioned as a true capture metagenomics pathogen detection solution for clinical diagnostics.
- 吉迅安® (Breast Cancer Precision Diagnostics) Breast cancer precision diagnostics product (吉迅安®) providing more accurate selection capabilities to support breast cancer treatment decisions.
Quantifiable outcome
- TRACELib002 project results published in Signal Transduction and Targeted Therapy (IF: 40.8), demonstrating clinical evidence for lung cancer immunotherapy value
Companies that use Gene+
Customer profileSegments3 records
Ideal customer profiles3 records
Gene+ technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Gene+ partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights6 records
Gene+ competitors and assessment
Company assessmentRegional players
- Da An Gene: Da An Gene is a Sun Yat-sen University-affiliated Chinese molecular diagnostics company providing clinical PCR and NGS-based tests. It is a regional comparable in clinical molecular diagnostics, primarily serving southern Chinese hospital networks with overlapping precision oncology test menus.
Direct peers
- Novogene: Novogene is a leading NGS services provider offering genomic sequencing, bioinformatics, and clinical research services to pharmaceutical and academic customers globally. It directly competes with Gene+ across sequencing services, biomarker discovery, and pharma research enablement, with overlapping customer segments in hospitals and research institutions.
- Caris Life Sciences: Caris Life Sciences is a US-based precision medicine company offering molecular profiling, AI-driven biomarker discovery, and pharma services. Its multi-omics profiling platform and pharma services business model closely parallel Gene+'s AI multi-omics platform and drug R&D enablement solutions.
- Annoroad Gene Technology: Annoroad Gene Technology is a Chinese genomics and precision medicine company providing NGS services, reproductive health diagnostics, and tumor testing. It is a direct competitor in clinical NGS diagnostics and serves similar hospital, pharma, and academic customers in China.
- Burning Rock Biotech: Burning Rock Biotech is a China-based precision oncology company specializing in NGS-based cancer diagnostics and pharma companion diagnostic services. It is a direct competitor in cancer precision diagnostics and pharma CDx, both serving Chinese hospitals and global pharmaceutical sponsors.
- Geneseeq Technology: Geneseeq Technology (Nanjing Geneseeq Technology) is a Chinese cancer genomics company providing NGS-based tumor profiling and companion diagnostic services. It directly competes with Gene+'s precision diagnostics business, particularly in lung and breast cancer panels, and serves overlapping pharma and hospital customers.
Broad incumbents
- WuXi AppTec: WuXi AppTec is the largest Chinese CRO/CDMO with a growing diagnostics and genomics services arm. While its core is small-molecule and biologics CRO, its clinical diagnostics and biomarker services overlap with Gene+'s pharma R&D enablement, making it a broad comparable for the precision medicine services category.
- BGI Genomics: BGI Genomics is the largest Chinese NGS services and precision medicine provider, offering clinical sequencing, cancer diagnostics, and pharma research services globally. BGI Group is also an early investor in Gene+, making it both a comparable and a competitive anchor; its scale, sequencing capacity, and hospital network set the competitive ceiling Gene+ must differentiate against in the Chinese market.
Emerging players
- Yuanqi Bio (HaploX): HaploX Biotechnology is a Chinese precision medicine company offering tumor NGS diagnostics, early cancer screening, and pharma services. It competes with Gene+ in the Chinese precision oncology and pharma CDx space, with comparable product offerings though typically smaller geographic reach.
- OrigiMed: OrigiMed is a Chinese precision oncology company focused on tumor NGS panel testing and pharmaceutical companion diagnostic services. It directly competes with Gene+ in cancer precision diagnostics and pharma CDx services in the Chinese market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Gene+ social profiles
Digital presenceGene+ compliance and trust
Trust signalCompliance1 record
Gene+ financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gene+ leadership team
Management profileNumber of profiles
Profiles2 records
Gene+ funding detail
Funding detailFunding overview
Funding rounds5 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gene+ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gene+
What does Gene+ do?
Gene+ (吉因加) is an AI-empowered precision medicine company that develops and operates an AI-driven multi-omics technology platform integrating biomarker discovery and validation, product development, and commercialization. It sells three categories of customized solutions — Drug R&D Enablement Solutions, Precision Diagnostics Solutions (NGS-based automated platforms), and Clinical Research & Translation Solutions — to hospitals, pharmaceutical and biotechnology companies, and medical research institutions across China and international markets.
Is Gene+ a public or private company?
Gene+ is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gene+ founded?
Gene+ was founded in 2015. It employs 11 to 50 people.
Where is Gene+ based?
Gene+ is headquartered in Changping, China, in the Asia region.
Who are Gene+'s main competitors?
Da An Gene is listed as a regional player. Direct peers are Novogene, Caris Life Sciences, Annoroad Gene Technology, Burning Rock Biotech and Geneseeq Technology. Broad incumbents are WuXi AppTec and BGI Genomics. Emerging players are Yuanqi Bio (HaploX) and OrigiMed.
Does Gene+ have an API?
No public API is recorded for Gene+.
What industry is Gene+ in?
Gene+'s product category is Precision Medicine. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.